Anti-IgLON5 Disease: A Long-course Presentation with a Response to Immunotherapy

Javier Villacieros-Álvarez, MD; Carlos Manuel Ordás, MD; Gustavo Torres-Gaona, MD; Ana Díez-Barrio, MD; Cristina Prieto-Jurczynska, MD; Carles Gaig, PhD

Corresponding Author:
Javier Villacieros-Álvarez
jvillacieros90@gmail.com

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
Affiliation Information for All Authors:

Javier Villacieros-Álvarez, Department of Neurology, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain. Department of Neurology, Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain. Department of Neurology, Hospital General de Villalba, Collado Villalba, Madrid, Spain.

Carlos Manuel Ordás, Department of Neurology, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain. Department of Neurology, Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain. Department of Neurology, Hospital General de Villalba, Collado Villalba, Madrid, Spain.

Gustavo Torres-Gaona, Department of Neurology, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain. Department of Neurology, Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain. Department of Neurology, Hospital General de Villalba, Collado Villalba, Madrid, Spain.

Ana Díez-Barrio, Department of Neurology, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain. Department of Neurology, Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain. Department of Neurology, Hospital General de Villalba, Collado Villalba, Madrid, Spain.

Cristina Prieto-Jurczynska, Department of Neurology, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain. Department of Neurology, Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain. Department of Neurology, Hospital General de Villalba, Collado Villalba, Madrid, Spain.

Carles Gaig, Department of Neurology, Hospital Clinic, Barcelona, Spain.

Number of characters in title: 80
Abstract Word count: 0
Word count of main text: 159
References: 2
Figures: 0
Tables: 0
Supplemental: Consent form signed by the patient Consent form signed by the patient’s daughter (assistant in the video).


Study funding: No targeted funding reported.
Disclosures: The authors report no disclosures relevant to the manuscript.
A 74-year-old woman presented with a 5-year history of progressive gait instability with recurrent falls, dysphonia, dysphagia and sleep problems which included insomnia, breathing difficulties and complex vocalizations during sleep (talking, singing, laughing, etc). Examination showed bilateral ptosis, upward gaze palsy, hoarseness, dysprosody and gait instability (video1). No parkinsonism, chorea or dementia were detected.

Brain MRI and PET as well as CSF parameters were unremarkable. A video-polysonmography revealed a disorganized sleep architecture but not parasomnia. Anti-IgLON5 antibodies were positive in CSF and serum by cell-based assay of HEK cells transfected with IgLON5 and immunohistochemistry on rat brain. HLA-genotyping detected HLA-DQB1*05:01.

Immunotherapy with intravenous methylprednisolone 1gr/day for five days and immunoglobulins resulted in improvement of gait and speech during a month (video1). Second course of immunoglobulins provided clinical stability.

Anti-IgLON5 disease represents a paradigm of autoimmune neurodegeneration with core features of a specific sleep disorder, bulbar symptoms and gait abnormalities\(^1\). Its recognition is important since some cases respond to immunotherapy\(^2\).
Video-http://links.lww.com/WNL/B300
Teaching Slides-http://links.lww.com/WNL/B301

References:


Video title:

Video 1. Patient affected with anti-IgLON5 disease, pre- and post-immunotherapy.

Video legend:

Video 1. The patient is describing her symptoms. Note the hoarseness and the dysprosody of the speech, as well as the bilateral ptosis. The oculomotor exam reveals an upward gaze palsy. Gait is very unsteady, requiring an assistance. After immunotherapy an improvement of the speech and gait is detected.
## Appendix 1: Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Javier Villacieros Álvarez, MD</td>
<td>Hospital Universitario Rey Juan Carlos, Madrid. Spain. Hospital Infanta Elena, Madrid. Spain. Hospital General de Villalba, Madrid. Spain.</td>
<td>Designed and conceptualized the study. Major role in acquisition of data. Drafted the manuscript for the intellectual content. Literature review.</td>
</tr>
<tr>
<td>Carlos Manuel Ordás Bandera, MD</td>
<td>Hospital Universitario Rey Juan Carlos, Madrid. Spain. Hospital Infanta Elena, Madrid. Spain. Hospital General de Villalba, Madrid. Spain.</td>
<td>Major role in acquisition of data. Critical review of the manuscript for intellectual content.</td>
</tr>
<tr>
<td>Gustavo Torres Gaona, MD</td>
<td>Hospital Universitario Rey Juan Carlos, Madrid. Spain. Hospital Infanta Elena, Madrid. Spain. Hospital General de Villalba, Madrid. Spain.</td>
<td>Major role in acquisition of data. Critical review of the manuscript for intellectual content.</td>
</tr>
<tr>
<td>Ana Díez Barrio, MD</td>
<td>Hospital Universitario Rey Juan Carlos, Madrid. Spain. Hospital Infanta Elena, Madrid. Spain.</td>
<td>Major role in acquisition of data. Critical review of the manuscript for intellectual content.</td>
</tr>
<tr>
<td>Author</td>
<td>Institution</td>
<td>Role</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>------</td>
</tr>
<tr>
<td>Cristina Prieto Jurczynska, MD</td>
<td>Hospital General de Villalba, Madrid. Spain.</td>
<td>Major role in acquisition of data. Critical review of the manuscript for intellectual content.</td>
</tr>
<tr>
<td></td>
<td>Hospital Universitario Rey Juan Carlos, Madrid. Spain.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hospital Infanta Elena, Madrid. Spain.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hospital General de Villalba, Madrid. Spain.</td>
<td></td>
</tr>
<tr>
<td>Carles Gaig, MD, PhD</td>
<td>Hospital Clínic, Barcelona, Spain.</td>
<td>Major role in acquisition of data. Critical review of the manuscript for intellectual content.</td>
</tr>
</tbody>
</table>
Anti-IgLON5 Disease: A Long-course Presentation with a Response to Immunotherapy
Neurology published online December 22, 2020
DOI 10.1212/WNL.000000000011381

This information is current as of December 22, 2020

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/early/2020/12/22/WNL.000000000011381.citation.full

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Clinical Neurology
http://n.neurology.org/cgi/collection/all_clinical_neurology
Autoimmune diseases
http://n.neurology.org/cgi/collection/autoimmune_diseases

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise